Special Issue "The Role of Thrombosis and Haemostasis in Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 30 November 2018
Prof. Dr. Marco Falasca
Cancer-associated thrombosis is a lethal complication in cancer sufferers. The association between malignancy and thrombosis was first described over a century and half ago, by Jean-Baptiste Bouillard in 1823 and later in 1865 by Armand Trousseau. It is now well accepted that cancer patients are at an estimated four to seven-fold increased risk of developing venous thromboembolism (VTE) compared to non-cancer patients. The mechanisms by which cancer elicit thromboembolic events are not entirely understood. A significant role is attributed to the capability of cancer cells to activate the coagulation system, thus inducing a hypercoagulable or prothrombotic state in cancer patients. Cancer cells can activate the coagulation cascade through the expression of tissue factor, the release of proinflammatory cytokines, and interactions with endothelial and circulating blood cells. Platelets, a key regulator cell population of haemostasis and thrombosis, are known to be an important contributor of VTE, not only to through their involvement in thrombus formation but also in promoting cancer survival and spread. Recently, neutrophils are implicated as an important mediator of cancer-associated thrombosis. Neutrophil extracellular traps (NETs), released from activated neutrophils, have been reported in tumour samples and their presence in vivo is associated with metastasis.
This Special Issue will cover the current research of thrombosis and haemostasis in cancer development. Both basic mechanisms underlying the processes, clinical observations and therapeutic implications of targeting key regulators of thrombosis and haemostasis will be discussedProf. Dr. Marco Falasca
Dr. Pat Metharom
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer biology
- cancer-associated thrombosis
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Cancer-associated thrombosis: mechanisms, treatment and implications for cancer metastasis
Authors: Norbaini Abdol Razak and Pat Metharom
Abstract: Cancer-associated thrombosis is a major cause of mortality in cancer patients, the most common type being venous thromboembolism (VTE). Several risk factors for developing VTE coexist with cancer patients, such as chemotherapy and immobilisation, contributing to the increased risk cancer patients have of developing VTE compared to non-cancer patients. Cancer cells are capable of activating the coagulation cascade and other pro-thrombotic properties of host cells, and many anti-cancer treatments themselves are being described as additional mechanisms for promoting VTE. Furthermore, studies have reported that coagulation and haemostatic activation in cancer may also contribute to tumour progression and metastasis. This review will discuss the multiple mechanisms involved in cancer-associated thrombosis including the role of anti-cancer drugs, the current treatment strategies available for VTE in cancer patients, and the existing associations of thrombosis and tumour progression in cancer patients.
Title: The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism
Authors: Hanny Al-Samkari 1 and Jean M. Connors 2
1 Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
2 Brigham & Women’s Hospital, Harvard Medical School, Boston, MA, USA
Abstract: Venous thromboembolism (VTE) complicates the clinical course of approximately 5-10% of all cancer patients. Anticoagulation of the cancer patient often presents unique challenges as these patients have both a higher risk of recurrent VTE and a higher risk of bleeding than patients without cancer. Although low molecular weight heparins (LMWH) are the standard of care for the management of cancer-associated VTE, their use requires once or twice daily subcutaneous injections, which can be a significant burden for many cancer patients who often require a long duration of anticoagulation. The direct oral anticoagulants (DOAC) are attractive options for patients with malignancy. DOAC offer immediate onset of action and short half- lives, properties similar to LMWH, but the oral route of administration is a significant advantage. Given the higher risks of recurrent VTE and bleeding, there has been concern about the efficacy and safety of DOAC in this patient population. Data are now emerging for the use of DOAC in the cancer patient population from dedicated clinical trials. While recently published data suggest that DOAC hold promise for the treatment of cancer associated VTE, additional studies are needed to establish DOAC as the standard-of-care treatment. Many such studies are currently underway. The available data for the use of DOAC in the treatment of cancer-associated VTE will be reviewed, focusing on efficacy, safety, and other considerations relevant to the cancer patient.
Title: Use of DOACs in Cancer-Related Venous Thromboembolism
Authors: Francesco Grandoni and Lorenzo Alberio
Abstract: Cancer patients develop a hypercoagulable state with a four- to seven-fold higher thromboembolic risk compared to non-cancer patients. Thromboembolic events can precede the diagnosis of cancer but they more often occur at diagnosis or during treatment. After malignancy itself, they represents the second cause of deaths. Low molecular weight heparins are the backbone of the treatment of cancer-associated thromboembolism. This treatment paradigm is possibly changing, as direct oral anticoagulants (DOACs) may prove to be an alternative therapeutic option. The currently available DOACs were approved during the first and second decades of the 21st century for various clinical indications. Three molecules (apixaban, edoxaban, rivaroxaban) are targeting the activated factor X and one (dabigatran) is directed against the activated factor II. The major trials analyzed the effect of these agents in the general population, with only a small portion of cancer patients. One published and several ongoing studies are specifically investigating the use of DOACs in cancer-associated thromboembolism. This article will review the current available literature on the use of DOACs in cancer patients. Moreover, we will discuss published data suggesting potential anti-cancer actions exerted by non-anticoagulant effects of DOAC. As soon as more prospective data will be available, DOACs are likely to be considered as a potential new therapeutic possibility in the armamentarium for the cancer-associated thromboembolism.
Title: Thrombin Generation and Cancer: Contributors and Consequences
Authors: Caroline Reddel, Chuen Wen Tan and Vivien Chen
Abstract: The high occurrence of cancer-associated thrombosis is associated with elevated thrombin generation. Tumour cells increase the potential for thrombin generation both directly, through the release of procoagulant factors, and indirectly, through the release of signals that activate other cell types (including platelets, leukocytes and erythrocytes) to promote thrombin generation, or direct action on those cells. Further, cancer treatments can worsen these effects. Coagulation factors, including tissue factor, and inhibitors of coagulation are altered and extracellular vesicles, which can promote and support thrombin generation, are released by tumour and other cells. Some phosphatidylserine expressing platelet subsets and platelet-derived EVs provide the surface for the assembly of coagulation factors essential for thrombin generation in-vivo. This review will explore the causes of increased thrombin production in cancer, and the availability and utility of tests and biomarkers. Increased thrombin production not only increases blood coagulation, but also promotes tumour growth and metastasis and as a consequence, thrombin and its contributors present opportunities for treatment of cancer-associated thrombosis and cancer itself.